Molecular pathology for classification of tumors and for efficacy prediction of qualified therapies is usually a fast escalating industry. The advice is partly determined by new evidence ensuing from a scientific overview from the Cochrane Collaboration [102]. Examining the data of RCTs coping with hypofractionated RT, the authors considerably https://valeriust641jqz7.wikibyby.com/user